It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVCR’s FA Score shows that 1 FA rating(s) are green whileSTAA’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVCR’s TA Score shows that 5 TA indicator(s) are bullish while STAA’s TA Score has 3 bullish TA indicator(s).
NVCR (@Medical/Nursing Services) experienced а +3.97% price change this week, while STAA (@Pharmaceuticals: Other) price change was -1.79% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +3.30%. For the same industry, the average monthly price growth was +5.08%, and the average quarterly price growth was +6.02%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.82%. For the same industry, the average monthly price growth was +1.66%, and the average quarterly price growth was +6.20%.
NVCR is expected to report earnings on Oct 23, 2025.
STAA is expected to report earnings on Oct 29, 2025.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-0.82% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
NVCR | STAA | NVCR / STAA | |
Capitalization | 1.42B | 1.35B | 105% |
EBITDA | -110.77M | -73.24M | 151% |
Gain YTD | -57.399 | 11.836 | -485% |
P/E Ratio | N/A | 49.73 | - |
Revenue | 630M | 224M | 281% |
Total Cash | 912M | 190M | 480% |
Total Debt | 700M | 40.5M | 1,728% |
NVCR | STAA | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 64 | 42 | |
P/E GROWTH RATING 1..100 | 9 | 87 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STAA's Valuation (86) in the Medical Specialties industry is in the same range as NVCR (100). This means that STAA’s stock grew similarly to NVCR’s over the last 12 months.
STAA's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NVCR (100). This means that STAA’s stock grew similarly to NVCR’s over the last 12 months.
STAA's SMR Rating (96) in the Medical Specialties industry is in the same range as NVCR (98). This means that STAA’s stock grew similarly to NVCR’s over the last 12 months.
STAA's Price Growth Rating (42) in the Medical Specialties industry is in the same range as NVCR (64). This means that STAA’s stock grew similarly to NVCR’s over the last 12 months.
NVCR's P/E Growth Rating (9) in the Medical Specialties industry is significantly better than the same rating for STAA (87). This means that NVCR’s stock grew significantly faster than STAA’s over the last 12 months.
NVCR | STAA | |
---|---|---|
RSI ODDS (%) | 6 days ago71% | 1 day ago79% |
Stochastic ODDS (%) | 2 days ago85% | 1 day ago75% |
Momentum ODDS (%) | 3 days ago75% | 1 day ago80% |
MACD ODDS (%) | 3 days ago70% | 1 day ago90% |
TrendWeek ODDS (%) | 2 days ago74% | 1 day ago83% |
TrendMonth ODDS (%) | 2 days ago79% | 1 day ago84% |
Advances ODDS (%) | 9 days ago75% | 13 days ago74% |
Declines ODDS (%) | 14 days ago90% | 1 day ago86% |
BollingerBands ODDS (%) | 2 days ago81% | 1 day ago75% |
Aroon ODDS (%) | 2 days ago79% | 1 day ago71% |
A.I.dvisor indicates that over the last year, NVCR has been loosely correlated with ITGR. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCR jumps, then ITGR could also see price increases.
Ticker / NAME | Correlation To NVCR | 1D Price Change % | ||
---|---|---|---|---|
NVCR | 100% | +0.12% | ||
ITGR - NVCR | 41% Loosely correlated | -0.37% | ||
BLFS - NVCR | 39% Loosely correlated | -1.52% | ||
ALGN - NVCR | 38% Loosely correlated | -1.81% | ||
AZTA - NVCR | 38% Loosely correlated | -0.42% | ||
CERS - NVCR | 37% Loosely correlated | -1.59% | ||
More |